-
Mashup Score: 2
Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders
Source: oncologypro.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6ESMO Virtual Plenary: February 2023 - 1 year(s) ago
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOVirtualPlenary: Stay up to date with the latest in #gastriccancer & #GEJcancer. Join this live discussion with top experts – now featuring @AACR expert commentary. ⏰ 16 & 17 Feb https://t.co/UfPeJwfE3m @FlorianLordick @LizzySmyth1 @BHenickMD https://t.co/wSJ7iGuOfQ
-
-
Mashup Score: 1
2023 ASCO Gastrointestinal Cancers Symposium Filippo Pietrantonio, MD, of Italy’s Istituto Nazionale dei Tumori, discusses phase II results from the INFINITY trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability–high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). These results open the way to…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Filippo Pietrantonio, MD, on Gastric or Gastroesophageal Junction Adenocarcinoma: Recent Data on Treatment With Tremelimumab and Durvalumab https://t.co/4mCFmINWYM #GEJCancer #stcsm #oncology #gastriccancer #GI23 @FilippoPietran4
-
-
Mashup Score: 0Novel Treatment Shows Early Promise for Gastric Cancer - 2 year(s) ago
A novel antibody acting on both PD-1 and CTLA4 has shown activity in first-line treatment of gastric and gastroesophageal junction cancer.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results from new phase 1b/2 study show that combo treatment with the antibody AK104 shows promise for patients with gastric and gastroesophageal junction cancer. https://t.co/DIFnmbNwWB #gejcancer
-
-
Mashup Score: 0Immunotherapy Likely New Standard in Advanced Esophageal Cancer - 3 year(s) ago
Nivolumab with chemotherapy or nivolumab with ipilimumab improved overall survival as compared with standard chemotherapy in advanced ESCC.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Immunotherapy drugs nivolumab and ipilimumab will most likely be the new standard going forward in treating patients with #gejcancer. https://t.co/aPhWn8QfUu
-
-
Mashup Score: 19
The addition of pembrolizumab to trastuzumab plus chemotherapy leads to superior overall response rate (ORR) compared with trastuzumab plus chemotherapy alone among patients with HER2-positive unresectable or metastatic gastric and gastroesophageal junction cancer (GEJ), according to the first interim analysis of the global, phase III KEYNOTE-811 trial (Abstract 4013).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
First interim results of KEYNOTE-811 suggest #Pembrolizumab may become part of the standard of care for patients w HER2-positive advanced #gastriccancer and #GEJcancer ➡️ https://t.co/mzaOdkhx5V @NataliyaUboha @YJanjigianMD #ASCO21 #ASCODailyNews #gicsm
-
-
Mashup Score: 0Trastuzumab Deruxtecan Brings HER2 Targeted Therapy to 3L HER2+ Advanced Gastric cancer/GEJ Cancers - 3 year(s) ago
In an interview with Targeted Oncology, Yelena Y. Janjigian, MD, provided important highlights from the DESTINY-Gastric01 trial and explained the overall impact of the FDA approval of trastuzumab deruxtecan for oncologists treating patients with HER2-positive advanced gastric cancer or GEJ cancers.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This expert shared her thoughts on the FDA approval of trastuzumab deruxtecan in patients with HER2-positive advanced gastric cancer or GEJ cancers. https://t.co/Ezh49FVzpH #GEJCancer
-
#ESMOVirtualPlenary abstract now available: Pembrolizumab plus chemotherapy as 1st-line tx for adv. HER2-negative gastric or gastroesophageal junction cancer: Phase III KEYNOTE-859 study. https://t.co/B2u1XxJsH8 @FlorianLordick @LizzySmyth1 #gastriccancer #GEJcancer @BHenickMD https://t.co/4TKUwe0AXW